Arcturus Therapeutics Holdings (ARCT) Return on Invested Capital (2023 - 2024)

Arcturus Therapeutics Holdings (ARCT) posted Return on Invested Capital of 0.26% for Q2 2024, up 27.86% on a QoQ basis from 0.36% in Q1 2024.

Arcturus Therapeutics Holdings (ARCT) Return on Invested Capital (2023 - 2024) Analysis & Trends

Arcturus Therapeutics Holdings' Return on Invested Capital history runs 2 years deep, the most recent figure standing at 0.26% for Q2 2024.

Quarterly Return on Invested Capital changed N/A year-over-year to 0.26% in Q2 2024, while the trailing twelve-month figure through Jun 2024 was 0.26% (changed N/A YoY) and the FY2022 annual result came in at 0.01%, changed N/A from the prior year.
Return on Invested Capital was 0.26% for Q2 2024 at Arcturus Therapeutics Holdings, up from 0.36% in the prior quarter.
Across five years, Return on Invested Capital topped out at 0.03% in Q3 2023 and bottomed at 0.36% in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROIC (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.00%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.04%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Arcturus Therapeutics Holdings	164.57 Mn	-46.81 Mn	-	-

Download Data